Reply
James Hamilton, Svetlana Lutsenko – 4 March 2016
STAT order: Should patients with chronic liver disease be prescribed statins to prevent fibrosis progression and hepatocellular carcinoma?
Juan G. Abraldes, Kelly W. Burak – 4 March 2016
Reply
Kai‐Henrik Peiffer, Lisa Sommer, Stefan Zeuzem, Christoph Sarrazin – 4 March 2016
Questions for esophageal stents treatment in acute refractory esophageal variceal bleeding
Chenguang Dai, Lili Zhao, Li Liu, Xiang Wang, Min Wang, Zhining Fan – 3 March 2016
Reply
Angels Escorsell, Jaime Bosch – 3 March 2016
Early readmissions after liver transplantation and the power of quality improvement
Elliot B. Tapper – 3 March 2016
Alcoholic hepatitis: Translational approaches to develop targeted therapies
Pranoti Mandrekar, Ramon Bataller, Hidekazu Tsukamoto, Bin Gao – 3 March 2016 – Alcoholic liver disease is a leading cause of liver‐related mortality worldwide. In contrast to recent advances in therapeutic strategies for patients with viral hepatitis, there is a significant lack of novel therapeutic options for patients with alcoholic liver disease. In particular, there is an urgent need to focus our efforts on effective therapeutic interventions for alcoholic hepatitis (AH), the most severe form of alcoholic liver disease.
Aspirin use and the risk of cholangiocarcinoma
Jonggi Choi, Hassan M. Ghoz, Thoetchai Peeraphatdit, Esha Baichoo, Benyam D. Addissie, William S. Harmsen, Terry M. Therneau, Janet E. Olson, Roongruedee Chaiteerakij, Lewis R. Roberts – 3 March 2016 – Whether aspirin use is protective against cholangiocarcinoma (CCA) remains unclear. We determined the association between aspirin use and other risk factors for each CCA subtype individually. In a hospital‐based case‐control study, 2395 CCA cases (1169 intrahepatic, 995 perihilar, and 231 distal) seen at the Mayo Clinic, Rochester, MN, from 2000 through 2014 were enrolled.